PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29433086-7	2018	Pretreatment with the CCK1 receptor (CCK1R) antagonist SR 27897 and CCK2 receptor (CCK2R) antagonist L-365,260 attenuated anorexia induction by both CCK- and T-2 toxin in a dose dependent manner.	l-365	101-106	cholecystokinin B receptor	Homo sapiens	68-81	
29433086-7	2018	Pretreatment with the CCK1 receptor (CCK1R) antagonist SR 27897 and CCK2 receptor (CCK2R) antagonist L-365,260 attenuated anorexia induction by both CCK- and T-2 toxin in a dose dependent manner.	l-365	101-106	cholecystokinin B receptor	Homo sapiens	83-88	
10636070-7	1999	RESULTS: The cell line LN 36 responded with increased cell number to stimulation by gastrin-17 and decreased cell number to inhibition by the CCK-B receptor antagonist L-365,260.	l-365	168-173	cholecystokinin B receptor	Homo sapiens	142-156	
16998832-15	2006	Overexpression of CCK2R by stable transfection of CCK2R plasmid amplified this increase and incubation with 1 microM L-365,260, a specific CCK2R antagonist, completely inhibited the effect of gastrin.	l-365	117-122	cholecystokinin B receptor	Homo sapiens	18-23	
24385417-6	2014	Furthermore, the CCK1 receptor antagonist SR 27897 and the CCK2 receptor antagonist L-365,260 dose-dependently attenuated both CCK- and DON-induced anorexia, which was consistent with this gut satiety hormone being an important mediator of 8-ketotrichothecene-induced food refusal.	l-365	84-89	cholecystokinin B receptor	Homo sapiens	59-72	
15655524-4	2005	Both these stimulating effects were abolished by L-365,260 or GV150013 (CCK-2 receptor antagonists), but were unaffected by SC-560 (COX-1 inhibitor).	l-365	49-54	cholecystokinin B receptor	Homo sapiens	72-86	
7786960-0	1995	A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.	l-365	30-35	cholecystokinin B receptor	Homo sapiens	43-47	
8928909-6	1996	Growth of BxPC-3 human pancreatic cancer cell in serum-free medium was inhibited by the addition of the CCK-B/gastrin receptor antagonist L-365,260, and gastrin treatment reversed the inhibitory effect of the antagonist.	l-365	138-143	cholecystokinin B receptor	Homo sapiens	104-109	
9296353-5	1997	In contrast, the structurally similar CCK-B receptor antagonist L-365,260 [3R(+)-N-[2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin -3-yl]-N"-(methylphenyl)urea; 30 nM-10 microM] produced progressive rightward shifts in the CCK-4 concentration-response curve, with no effect observed on the CCK-4 maximum response.	l-365	64-69	cholecystokinin B receptor	Homo sapiens	38-52	
7786960-4	1995	Therefore, the present multicenter, placebo-controlled, double-blind trial was designed to investigate the efficacy of L-365,260, a CCKB antagonist, in patients with panic disorder with or without agoraphobia.	l-365	119-124	cholecystokinin B receptor	Homo sapiens	132-136	
8335062-6	1993	The selective non-peptide CCKB receptor antagonist L-365,260 was more potent than the selective CCKA receptor antagonist MK-329 in inhibiting the [Ca2+]i mobilization elicited by 10 nM CCK-8 with IC50 values of 20 +/- 8 nM and 400 +/- 100 nM, respectively.	l-365	51-56	cholecystokinin B receptor	Homo sapiens	26-30	
10467593-2	1994	Here, we report that the memory-enhancing effect of the CCK-B receptor antagonist L-365,260 (1 mg/kg i.p.	l-365	82-87	cholecystokinin B receptor	Homo sapiens	56-70	
8192551-1	1994	BACKGROUND: We investigated whether the selective brain cholecystokinin (CCKB) receptor antagonist, L-365,260, could antagonize the panicogenic effects of CCK-tetrapeptide (CCK-4) in patients with panic disorder.	l-365	100-105	cholecystokinin B receptor	Homo sapiens	50-87	
8222496-0	1993	The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans.	l-365	32-37	cholecystokinin B receptor	Homo sapiens	4-20	
1728842-2	1992	This paper reviews experiments in which devazepide (a selective CCK-A receptor antagonist) and L-365,260 (a selective CCK-B-gastrin receptor antagonist) have been used.	l-365	95-100	cholecystokinin B receptor	Homo sapiens	118-123